• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Eloxx Pharmaceuticals, Inc.

    4/13/21 2:05:48 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELOX alert in real time by email
    SC 13D 1 formsc13d.htm FORM SC 13D Thompson Legal Advisory Services: Form SC 13D - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934 (Amendment No. )*

    Eloxx Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, $0.01 par value per share

    (Title of Class of Securities)


    29014R103

    (CUSIP Number)


    Kaasim Mahmood

    Advent Life Sciences LLP

    158-160 North Gower Street

    London NW1 2ND

    United Kingdom

    +44 (0) 207 932 2100

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    April 1, 2021

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  [  ].

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See 240.13d-7(b) for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1

    NAMES OF REPORTING PERSONS

    Advent Life Sciences LLP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  [  ]

    (b)  [  ]

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

    [  ]

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

     

    8

    SHARED VOTING POWER

     

    2,532,270 (See Item 5)

     

    9

    SOLE DISPOSITIVE POWER

     

    0

     

    10

    SHARED DISPOSITIVE POWER

     

    2,532,270 (See Item 5)

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,532,270 (See Item 5)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

    [  ]

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.3% (See Item 5)

    14

    TYPE OF REPORTING PERSON (See Instructions)

    PN

             



    1

    NAMES OF REPORTING PERSONS

    Advent Life Sciences Fund II LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  [  ]

    (b)  [  ]

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

    [  ]

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

     

    8

    SHARED VOTING POWER

     

    2,532,270 (See Item 5)

     

    9

    SOLE DISPOSITIVE POWER

     

    0

     

    10

    SHARED DISPOSITIVE POWER

     

    2,532,270 (See Item 5)

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,532,270 (See Item 5)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

    [  ]

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.3% (See Item 5)

    14

    TYPE OF REPORTING PERSON (See Instructions)

    PN

             



    1

    NAMES OF REPORTING PERSONS

    Rajesh Parekh

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  [  ]

    (b)  [  ]

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

    [  ]

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

     

     

    8

    SHARED VOTING POWER

     

    2,532,270 (See Item 5)

     

    9

    SOLE DISPOSITIVE POWER

     

     

     

    10

    SHARED DISPOSITIVE POWER

     

    2,532,270 (See Item 5)

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,532,270 (See Item 5)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

    [  ]

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.3% (See Item 5)

    14

    TYPE OF REPORTING PERSON (See Instructions)

    IN

             



    1

    NAMES OF REPORTING PERSONS

    Shahzad Malik

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  [  ]

    (b)  [  ]

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

    [  ]

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

     

     

    8

    SHARED VOTING POWER

     

    2,532,270 (See Item 5)

     

    9

    SOLE DISPOSITIVE POWER

     

     

     

    10

    SHARED DISPOSITIVE POWER

     

    2,532,270 (See Item 5)

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,532,270 (See Item 5)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

    [  ]

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.3% (See Item 5)

    14

    TYPE OF REPORTING PERSON (See Instructions)

    IN

             



    1

    NAMES OF REPORTING PERSONS

    Kaasim Mahmood

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  [  ]

    (b)  [  ]

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

    [  ]

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

     

     

    8

    SHARED VOTING POWER

     

    2,532,270 (See Item 5)

     

    9

    SOLE DISPOSITIVE POWER

     

     

     

    10

    SHARED DISPOSITIVE POWER

     

    2,532,270 (See Item 5)

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,532,270 (See Item 5)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

    [  ]

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.3% (See Item 5)

    14

    TYPE OF REPORTING PERSON (See Instructions)

    IN

             


    Item 1. Security and Issuer

    (a) The class of equity securities to which this statement on Schedule 13D relates is the Common Stock of the Issuer.

    (b) The address of the principal executive offices of the Issuer is 950 Winter Street, Waltham, MA 02451.

    Item 2. Identity and Background

    (a) The Reporting Persons are:

    1. Advent Life Sciences LLP ("Advent")

    2. Advent Life Sciences Fund II LP (the "Advent Fund")

    3. Rajesh Parekh

    4. Shahzad Malik

    5. Kaasim Mahmood

    (b) The principal business office of each of the Reporting Persons and Advent Life Sciences GP LLP, the general partner of the Advent Fund ("Advent GP") is located at 158-160 North Gower Street, London NW1 2ND, United Kingdom.

    (c) Advent and the Advent Fund are entities engaged in investment activities; Advent also is in the business of acting as the manager of the Advent Fund and a member of Advent GP. Advent GP is the general partner of the Advent Fund.  The principal business of Dr. Parekh, Dr. Malik and Dr. Mahmood are to serve as general partners of Advent and engage in other investment activities.  Dr. Parekh is also a member of the Issuer's board of directors (the "Board") and those of other private and public companies.  Dr. Malik and Dr. Mahmood are also members of the board of directors of various private and public companies.

    (d) None of the Reporting Persons nor Advent GP, during the last five years, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) None of the Reporting Persons nor Advent GP, during the last five years, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) Each of Advent and Advent GP is a limited liability partnership organized under the laws of the United Kingdom.  The Advent Fund is a limited partnership organized under the laws of the United Kingdom.  Each of Dr. Parekh, Dr. Malik and Dr. Mahmood is a citizen of the United Kingdom.


    Item 3. Source and Amount of Funds or Other Considerations

    All of the 2,532,270 shares of Common Stock were received on April 1, 2021 in exchange for 10,060,920 shares of Series A Preferred Stock and 38,461,538 shares of Series A-1 Preferred Stock of Zikani Therapeutics, Inc. ("Zikani") held by Advent and the Advent Fund in connection with the acquisition of Zikani by the Issuer pursuant to that certain Agreement and Plan of Merger, dated April 1, 2021, by and among the Issuer, Delta Merger Sub Acquisition Corporation and Zikani.

    Item 4. Purpose of Transaction

    The information set forth in Item 3 is incorporated herein by reference.

    Advent and the Advent Fund hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the Board and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer, which could include items in subparagraphs (a) through (j) of Schedule 13D.

    Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding the Issuer, and whether to acquire additional securities of the Issuer (by means of open market purchases, privately negotiated purchases, exercise some of all of the Stock Options, or otherwise) or to dispose of some or all of the securities of the Issuer under their control. 

    Except as otherwise disclosed herein, and subject to Dr. Parekh's duties and responsibilities as a member of the Board, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

    Item 5. Interest in Securities of the Issuer

    (a) Items 7 through 11 and 13 of each of the cover pages of this statement on Schedule 13D are incorporated herein by reference.

    All percentages of ownership of Common Stock by the Reporting Persons in this statement on Schedule 13D assume an aggregate of 40,214,873 shares of Common Stock issued and outstanding as of March 25, 2021, as reported by the Issuer on the Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission by the Issuer on April 1, 2021.

    (b) Items 7 through 11 and 13 of each of the cover pages of this statement on Schedule 13D are incorporated herein by reference.

    The Reporting Persons disclaim beneficial ownership of the securities held by each of the other Reporting Persons, and this statement on Schedule 13D shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose, except to the extent that any such Reporting Persons actually exercise voting or dispositive power with respect to such securities.


    (c) The information set forth in Item 3 is hereby incorporated by reference. Except as disclosed herein and except for an option to purchase 40,000 shares of Common Stock of the Issuer granted by the Issuer to Dr. Parekh on April 1, 2021 in connection with his appointment to the Board, none of which is subject to vesting within 60 days of this Schedule 13D, none of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past 60 days.

    (d) Except as set forth herein, no other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Ordinary Shares beneficially owned by the Reporting Persons.

    (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    The information in Item 3 is hereby incorporated herein by reference.

    Item 7. Material to Be Filed as Exhibits

    Exhibit

    Description

     

     

    I Agreement Regarding the Joint Filing of Schedule 13D by and among the Reporting Persons, dated as of April 8, 2021.
       
    II Agreement and Plan of Merger, dated April 1, 2021, by and among Eloxx Pharmaceuticals, Inc., Delta Merger Sub Acquisition Corporation and Zikani Therapeutics, Inc., incorporated herein by reference to Exhibit 2.1 to the Issuer's Current Report on Form 8-K, filed on April 1, 2021.

     



    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  April 8, 2021

     

    ADVENT LIFE SCIENCES LLP

     

    By:       /s/ Rajesh Parekh                                        

    Rajesh Parekh, General Partner of Advent Life Sciences LLP

     

     

    ADVENT LIFE SCIENCES FUND II LP

     

    By:       /s/ Rajesh Parekh                                        

    Rajesh Parekh, General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund II LP

     

     

    /s/ Rajesh Parekh                                        

    RAJESH PAREKH

       
       
     

         /s/ Shahzad Malik                                                     

    SHAHZAD MALIK

       
       
     

         /s/ Kaasim Mahmood                                               

    KAASIM MAHMOOD

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).


    Exhibit I

    AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D

    Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attached as an Exhibit, and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned.  This Agreement may be executed in one or more counterparts.  Notwithstanding the foregoing, each of the undersigned disclaims beneficial ownership of the shares of the other, except to the extent of his or its pecuniary interest therein.

    Date:  April 8, 2021

     

    ADVENT LIFE SCIENCES LLP

     

    By:   /s/ Rajesh Parekh                                                        

    Rajesh Parekh, General Partner of Advent Life Sciences LLP

     

     

    ADVENT LIFE SCIENCES FUND II LP

     

    By:       /s/ Rajesh Parekh                                                        

    Rajesh Parekh, General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund II LP

       
     

     

    /s/ Rajesh Parekh                                                        

    RAJESH PAREKH

       
       
     

    /s/ Shahzad Malik                                                      

    SHAHZAD MALIK

       
       
     

    /s/ Kaasim Mahmood                                                

    KAASIM MAHMOOD

     

     


    Get the next $ELOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELOX

    DatePrice TargetRatingAnalyst
    12/17/2021$4.00Outperform
    Oppenheimer
    11/18/2021$2.00 → $1.00Neutral
    HC Wainwright & Co.
    11/11/2021$3.00 → $2.00Neutral
    HC Wainwright & Co.
    6/30/2021$3.10Buy
    Mizuho
    More analyst ratings

    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Eloxx Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Eloxx Pharmaceuticals with a rating of Outperform and set a new price target of $4.00

      12/17/21 5:45:41 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $1.00 from $2.00 previously

      11/18/21 6:16:16 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $2.00 from $3.00 previously

      11/11/21 6:39:05 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walts Alan Edmund was granted 12,000 shares, increasing direct ownership by 1,274% to 12,942 units (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:02:21 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Androski Lindsay was granted 12,000 shares (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:01:56 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Rubin Steven D was granted 12,000 shares (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:01:36 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

      Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subjects in Phase 1 trial of ZKN-013 WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases w

      11/12/24 4:05:00 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

      First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to advance our clinical programs WATERTOWN, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted gene

      7/11/24 11:46:35 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

      ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWI

      4/16/24 7:30:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.

      NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      11/19/24 4:01:28 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      10/17/24 4:01:29 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.

      NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      8/14/24 4:01:27 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

      Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp

      10/17/23 8:00:00 AM ET
      $ATAI
      $ATOS
      $ELOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

      SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc

      6/1/23 9:10:00 AM ET
      $ATAI
      $ATOS
      $ELOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Eloxx Pharmaceuticals Announces Changes to Board of Directors

      Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board's Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr.

      7/5/22 8:00:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Financials

    Live finance-specific insights

    See more
    • Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

      Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentially confounded by variability due to low drug exposure Path forward for ELX-02 for the treatment of Class 1 CF to be determined together with CF Foundation Company to host conference call and webcast today, September 14, 2022, at 4:30 p.m. ET WATERTOWN, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare d

      9/14/22 4:05:00 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

      ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, November 17, 2021 at 8:30 am ET WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare dise

      11/17/21 7:00:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB) Sumit Aggarwal, Zikani President and CEO, to Lead the Combined Company Eloxx to Issue Approximately 7.6 Million Shares to Zikani Stockholders Company to Host Investor Call at 8:30 a.m. ET, April 1 WALTHAM, Mass. and WATERTOWN, Mass., April 01, 2021 (GLOBE NEWSWIRE

      4/1/21 7:45:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Eloxx Pharmaceuticals Inc.

      SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      8/20/24 8:13:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/13/23 4:52:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/14/22 6:18:22 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care